In one aspect, the invention provides a protein capture membrane comprising a first side and a second side and a plurality of interstices extending contiguously from the first side to the second side, wherein the interstices are coated with a protein-reactive coating; and the porous substrate comprises nanoporous alumina or porous glass. In another aspect the invention provides a method of detecting a protein of interest in a plurality of proteins.

In a method for analyzing cells, a sample fluid having a suspending medium and cells is fed to a microfluidic device having at least one cell processing unit having a trapping region, a reaction unit, and an outlet arrangement. The trapping region is delimited by at least an input valve and a sieve valve, in particular a v-type valve that is capable of retaining the cells while letting fluids pass. The method includes trapping cells in the trapping region, subsequently establishing a flow of a reaction fluid through the trapping region while the sieve valve assumes the open state, such that the reaction fluid transfers the trapped cells from the trapping region into the reaction unit, decomposing the transferred cells into cell fragments through a decomposition process, collecting the cell fragments in the outlet arrangement, and analyzing the cell fragments.

A method for analyzing macromolecules, including peptides, polypeptides, and proteins, employing nucleic acid encoding is disclosed.

An object of the present invention is to provide a method for efficiently identifying a polyubiquitinated substrate which is generally not easily identified. The method for identifying a polyubiquitinated substrate includes (1) a step of expressing a trypsin-resistant polyubiquitin chain-binding protein and a ubiquitin ligase in a cell, (2) a step of isolating a complex that contains the trypsin-resistant polyubiquitin chain-binding protein from the cell having undergone the step (1), (3) a step of subjecting the complex isolated by the step (2) to trypsin digestion, and (4) a step of identifying a peptide that has a ubiquitination site from a digested material obtained by the step (3).

Disclosed are systems and methods for developing diagnostic tests (e.g., detection, screening, monitoring, and prognostic tests) based on biomarker information from legacy clinical sample sets, for which only small sample volumes (e.g., about 0.05 to about 1.0 mL or less per sample) are typically available. For example, biomarkers (e.g., about 10, 50, 100, 150, 200, 300, or more) may be detected in the clinical samples through the use of single molecule detection and each biomarker may be detected in an assay that includes about 1 or less of a legacy clinical sample.

Some embodiments disclosed herein provide a plurality of compositions each comprising a protein binding reagent conjugated with an oligonucleotide. The oligonucleotide comprises a unique identifier for the protein binding reagent it is conjugated with, and the protein binding reagent is capable of specifically binding to a protein target. Further disclosed are methods and kits for quantitative analysis of a plurality of protein targets in a sample and for simultaneous quantitative analysis of protein and nucleic acid targets in a sample. Also disclosed herein are systems and methods for preparing a labeled biomolecule reagent, including a labeled biomolecule agent comprising a protein binding reagent conjugated with an oligonucleotide.

Provided herein are methods of diagnosing and/or treating ACVS, by determining expression levels of several ACVS-related molecules, such as FABP3, ANPR-1, IGFBP-3, F9, SELL, apoB100, ADPN, vWF, THBS1, PRL, PON3, EGFR, VEGF-D, HPX, MBT, F5, F10, SERPIN A5, HCII, and HABP2, for example in a blood sample.

The present invention provides glycated Amadori products of the CD59 peptide and fragments thereof to be used as tools and among methods for the diagnosis and prognosis of pre-diabetes and diabetes. Certain aspects of the invention include glycated Amadori products of CD59 and fragments thereof to be used for the generation of antibodies and antibody fragments. Still other aspects of the invention include methodologies for the preparation of glycated Amadori products of CD59, fragments thereof, the inventive antibodies, and antibody fragments.

The present invention provides compositions and methods that can be used to determine a peptide signature for an antibody repertoire in a sample comprising multiple antibodies. The method can be used to characterize a phenotype in a sample, such as providing a diagnosis, prognosis or theranosis of a medical condition.

The present invention relates to the provision of antibody fragments capable of binding selectively to the Gal--(1.fwdarw.3)-Gal epitope. The invention further relates to assay systems comprising these antibody fragments for use in testing transplantation tissue for possible rejection complications. This epitope is often found on porcine tissue destined for human transplantation. The epitope is also found on biopharmaceuticals and on some infectious agents and accordingly the invention also provides assay systems for these applications.